Screening for 2‐quinolinone‐derived selective androgen receptor agonists in doping control analysis
- 8 October 2007
- journal article
- research article
- Published by Wiley in Rapid Communications in Mass Spectrometry
- Vol. 21 (21) , 3477-3486
Abstract
Selective androgen receptor modulators (SARMs) represent a class of emerging drugs with high potential for misuse in sports, and therefore members of this group are banned as anabolic agents by the World Anti‐Doping Agency. Preventive approaches to restrict their use include early implementation of target analytes into doping control screening assays and evaluation of the mass spectrometric behavior of these drugs to allow their unequivocal identification as well as the characterization of structurally related compounds and metabolic products. Four model SARMs with the 6‐alkylamino‐2‐quinolinone structure, including the advanced drug candidate LGD‐2226, were synthesized. Fragmentation pathways after positive electrospray ionization and collision‐induced dissociation were studied using an LTQ Orbitrap mass analyzer, and diagnostic product ions and common dissociation pathways were employed to establish a screening procedure targeting intact quinolinone‐based SARMs as well as putative metabolic products such as dealkylated analogues. Therefore, features of a triple quadrupole mass analyzer such as multiple reaction monitoring and precursor ion scanning were utilized. Sample preparation based on commonly employed liquid‐liquid extraction and subsequent liquid chromatographic/tandem mass spectrometric measurement allowed for detection limits of 0.01–0.2 ng/mL, and intra‐ and interday precisions between 3.2 and 8.5% and between 6.3 and 16.6%, respectively. Recoveries varied from 81 to 98%, and tests for ion suppression or enhancement effects were negative for all analytes. Copyright © 2007 John Wiley & Sons, Ltd.Keywords
This publication has 27 references indexed in Scilit:
- Male pubertal development and the role of androgen therapyNature Clinical Practice Endocrinology & Metabolism, 2007
- Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinonesBioorganic & Medicinal Chemistry Letters, 2007
- Feasibility of different mass spectrometric techniques and programs for automated metabolite profiling of tramadol in human urineRapid Communications in Mass Spectrometry, 2006
- Drug Insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and agingNature Clinical Practice Endocrinology & Metabolism, 2006
- Screening for metabolically stable aryl‐propionamide‐derived selective androgen receptor modulators for doping control purposesRapid Communications in Mass Spectrometry, 2006
- Nonsteroidal tissue selective androgen receptor modulators: a promising class of clinical candidatesExpert Opinion on Therapeutic Patents, 2005
- Another designer steroid: discovery, synthesis, and detection of ‘madol’ in urineRapid Communications in Mass Spectrometry, 2005
- QUANTITATIVE STRUCTURE-METABOLISM RELATIONSHIP MODELING OF METABOLIC N-DEALKYLATION REACTION RATESDrug Metabolism and Disposition, 2004
- Designer DopingExercise and Sport Sciences Reviews, 2004
- Androgen Replacement TherapyDrugs, 2004